A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
Clinical trial NCT05066646 · UNKNOWN
Trial details
- NCT number
- NCT05066646
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-01
- Primary completion
- 2022-10-01
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.